Abbott Laboratories $ABT Shares Acquired by Vise Technologies Inc.

Vise Technologies Inc. grew its holdings in Abbott Laboratories (NYSE:ABT) by 39.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 56,077 shares of the healthcare product maker’s stock after buying an additional 15,885 shares during the period. Vise Technologies Inc.’s holdings in Abbott Laboratories were worth $7,026,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Freemont Management S.A. lifted its position in Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after purchasing an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $116,580,000. Thrivent Financial for Lutherans raised its position in shares of Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth about $185,640,000. Finally, Net Worth Advisory Group acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $1,366,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Up 0.5%

Shares of NYSE ABT opened at $91.20 on Friday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The stock has a market cap of $158.85 billion, a PE ratio of 25.55, a P/E/G ratio of 1.51 and a beta of 0.63. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average of $92.80 and a 200 day moving average of $109.31.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ABT shares. Mizuho reduced their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. JPMorgan Chase & Co. reduced their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Barclays reduced their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. TD Cowen reduced their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $119.09.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.